Hemoperfusion in patients with severe COVID-19 respiratory failure, lifesaving or not?
COVID-19
hemoperfusion
respiratory failure
Journal
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
ISSN: 1735-1995
Titre abrégé: J Res Med Sci
Pays: India
ID NLM: 101235599
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
10
2020
revised:
28
10
2020
accepted:
18
01
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
5
8
2021
Statut:
epublish
Résumé
The new coronavirus outbreak quickly filled hospital beds and stunned the world. Intensive care is required for 5% of patients, and the mortality rate for critically ill patients is 49%. The "cytokine storm" is considered as the main cause of pathogenesis for coronavirus disease-19 (COVID-19)-related respiratory failure, hemoperfusion may be a modality for treatment of disease. Thirty-seven an patients with positive real-time polymerase chain reaction for SARStions2 in an upper respiratory tract sample or typical chest computed tomography lesion were eligible for this case-control study. Patients meeting the criteria for hemoperfusion including clinical and laboratory indices, were evaluated for outcomes such as hospitalization length and mortality. Patients were divided into three groups, i.e., patients who received hemoperfusion without a need for mechanical ventilation (MV), patients who received hemoperfusion before MV, and patients who received hemoperfusion after MV. Among 37 patients with COVID-19 respiratory failure, 32% were female with a mean age of 55.54 (standard deviation 14.1) years. There was no statistically significant difference between the three groups in terms of length of hospital stay and intensive care unit (ICU) stay (P-tayns: 0.593 and 0.243, respectively, confidence interval [CI]: 95%). Heart rate, respiratory rate, PaO It seems that applying hemoperfusion in the inflammatory phase of the disease, especially before the intubation, reduce the need for MV. However, hemoperfusion does not have any impacts on the duration of hospital and ICU stay.
Sections du résumé
BACKGROUND
BACKGROUND
The new coronavirus outbreak quickly filled hospital beds and stunned the world. Intensive care is required for 5% of patients, and the mortality rate for critically ill patients is 49%. The "cytokine storm" is considered as the main cause of pathogenesis for coronavirus disease-19 (COVID-19)-related respiratory failure, hemoperfusion may be a modality for treatment of disease.
MATERIALS AND METHODS
METHODS
Thirty-seven an patients with positive real-time polymerase chain reaction for SARStions2 in an upper respiratory tract sample or typical chest computed tomography lesion were eligible for this case-control study. Patients meeting the criteria for hemoperfusion including clinical and laboratory indices, were evaluated for outcomes such as hospitalization length and mortality. Patients were divided into three groups, i.e., patients who received hemoperfusion without a need for mechanical ventilation (MV), patients who received hemoperfusion before MV, and patients who received hemoperfusion after MV.
RESULTS
RESULTS
Among 37 patients with COVID-19 respiratory failure, 32% were female with a mean age of 55.54 (standard deviation 14.1) years. There was no statistically significant difference between the three groups in terms of length of hospital stay and intensive care unit (ICU) stay (P-tayns: 0.593 and 0.243, respectively, confidence interval [CI]: 95%). Heart rate, respiratory rate, PaO
CONCLUSION
CONCLUSIONS
It seems that applying hemoperfusion in the inflammatory phase of the disease, especially before the intubation, reduce the need for MV. However, hemoperfusion does not have any impacts on the duration of hospital and ICU stay.
Identifiants
pubmed: 34345245
doi: 10.4103/jrms.JRMS_1122_20
pii: JRMS-26-34
pmc: PMC8305775
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34Informations de copyright
Copyright: © 2021 Journal of Research in Medical Sciences.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Lancet Respir Med. 2020 Mar;8(3):240-241
pubmed: 32035509
PLoS One. 2017 Oct 30;12(10):e0187015
pubmed: 29084247
Crit Care. 2011;15(1):205
pubmed: 21371356
Ther Apher Dial. 2013 Aug;17(4):454-61
pubmed: 23931889
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
J Res Med Sci. 2019 Jan 31;24:2
pubmed: 30815015
World J Pediatr. 2020 Jun;16(3):240-246
pubmed: 32026148
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
PLoS Pathog. 2016 Dec 15;12(12):e1005973
pubmed: 27977798
JAMA. 2009 Jun 17;301(23):2445-52
pubmed: 19531784
Langenbecks Arch Surg. 2009 Mar;394(2):303-11
pubmed: 18685861
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Ther Apher Dial. 2010 Dec;14(6):596-602
pubmed: 21118369
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
J Crit Care. 2019 Feb;49:172-178
pubmed: 30448517
World J Emerg Med. 2012;3(1):44-8
pubmed: 25215038
Blood Purif. 2020;49(3):255-258
pubmed: 32172242
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Ann Intensive Care. 2017 Aug 14;7(1):84
pubmed: 28808944
Intensive Care Med. 2020 Apr;46(4):579-582
pubmed: 32103284